RS56793B1 - Cea antitela - Google Patents

Cea antitela

Info

Publication number
RS56793B1
RS56793B1 RS20180098A RSP20180098A RS56793B1 RS 56793 B1 RS56793 B1 RS 56793B1 RS 20180098 A RS20180098 A RS 20180098A RS P20180098 A RSP20180098 A RS P20180098A RS 56793 B1 RS56793 B1 RS 56793B1
Authority
RS
Serbia
Prior art keywords
cea antibodies
cea
antibodies
Prior art date
Application number
RS20180098A
Other languages
English (en)
Inventor
Thomas U Hofer
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of RS56793B1 publication Critical patent/RS56793B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RS20180098A 2011-03-02 2012-02-29 Cea antitela RS56793B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11156665 2011-03-02
PCT/EP2012/053390 WO2012117002A1 (en) 2011-03-02 2012-02-29 Cea antibodies
EP12707732.9A EP2681244B1 (en) 2011-03-02 2012-02-29 Cea antibodies

Publications (1)

Publication Number Publication Date
RS56793B1 true RS56793B1 (sr) 2018-04-30

Family

ID=45811481

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180098A RS56793B1 (sr) 2011-03-02 2012-02-29 Cea antitela

Country Status (35)

Country Link
US (7) US8642742B2 (sr)
EP (2) EP3333193A1 (sr)
JP (1) JP6046642B2 (sr)
KR (1) KR101981342B1 (sr)
CN (1) CN103403029B (sr)
AR (1) AR085591A1 (sr)
AU (1) AU2012222463B9 (sr)
BR (1) BR112013021460B1 (sr)
CA (1) CA2827722C (sr)
CL (1) CL2013002203A1 (sr)
CO (1) CO6781491A2 (sr)
CR (1) CR20130359A (sr)
DK (1) DK2681244T3 (sr)
EA (1) EA029300B1 (sr)
EC (1) ECSP13012859A (sr)
ES (1) ES2657856T3 (sr)
HK (1) HK1187056A1 (sr)
HR (1) HRP20180147T1 (sr)
HU (1) HUE036229T2 (sr)
IL (1) IL227482B (sr)
LT (1) LT2681244T (sr)
MA (1) MA34927B1 (sr)
MX (1) MX347590B (sr)
MY (1) MY164647A (sr)
NO (1) NO2681244T3 (sr)
PE (1) PE20141017A1 (sr)
PL (1) PL2681244T3 (sr)
PT (1) PT2681244T (sr)
RS (1) RS56793B1 (sr)
SG (1) SG192972A1 (sr)
SI (1) SI2681244T1 (sr)
TW (1) TWI553016B (sr)
UA (1) UA115030C2 (sr)
WO (1) WO2012117002A1 (sr)
ZA (1) ZA201305323B (sr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339608B (es) * 2009-08-31 2016-05-31 Roche Glycart Ag Anticuerpos del antigeno carcinoembrionario (cea).
DK3489255T3 (da) 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
UA115030C2 (uk) * 2011-03-02 2017-09-11 Рош Глікарт Аг Антитіло, яке зв'язується зі зв'язаним з мембраною карциноембріональним антигеном (сеа)
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
MY171100A (en) * 2012-11-20 2019-09-25 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
CA2892585C (en) 2012-12-03 2022-07-05 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
HUE043851T2 (hu) 2013-02-22 2019-09-30 Abbvie Stemcentrx Llc Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk
KR20210094673A (ko) 2013-02-26 2021-07-29 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
JP2014161283A (ja) * 2013-02-26 2014-09-08 Shizuoka Prefecture Ｃｅａｃａｍ５遺伝子のスプライシングバリアント
KR20150122203A (ko) * 2013-02-26 2015-10-30 로슈 글리카트 아게 T 세포 활성화 이중특이적 항원 결합 분자
EP3038634A4 (en) 2013-08-28 2017-10-11 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
SG11201601424PA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
AR100271A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Compuestos de vegfr2 / ang2
HUE044814T2 (hu) 2014-08-04 2019-11-28 Hoffmann La Roche Bispecifikus, T-sejt-aktiváló antigénkötõ molekulák
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
CA2990755A1 (en) 2015-10-02 2017-04-06 F. Hoffman-La Roche Ag Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
CN106065032B (zh) * 2015-11-30 2019-07-09 成都金昆生物科技有限公司 一新型蛋白结合片段
EP3178848A1 (en) * 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CA2997406C (en) 2015-12-09 2024-05-28 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
RU2652955C1 (ru) * 2015-12-24 2018-05-03 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Мономолекулярный химерный т-клеточный рецептор к раково-эмбриональному антигену
WO2017118675A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
CA3021098A1 (en) 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use
BR112019010064A2 (pt) 2016-11-18 2019-10-01 Astellas Pharma Inc novo fragmento fab do anticorpo muc1 anti-humano
AU2018250875A1 (en) 2017-04-13 2019-10-03 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN108219004A (zh) * 2018-02-08 2018-06-29 吉林省拓华生物科技有限公司 双特异嵌合抗原受体修饰的t细胞、其制备方法及用途
CN113166220A (zh) 2018-03-09 2021-07-23 奥美药业有限公司 创新细胞因子前药
US20210221908A1 (en) 2018-06-03 2021-07-22 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
SG11201913540VA (en) * 2019-03-15 2020-10-29 Japanese Found For Cancer Res Anti-Podoplanin Antibody
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
BR112021025034A2 (pt) 2019-06-13 2022-04-26 Bolt Biotherapeutics Inc Imunoconjugado, composto aminobenzazepina-ligante, composição farmacêutica, métodos para tratar câncer e para preparar um imunoconjugado e uso de um imunoconjugado
CN113906053B (zh) * 2019-06-26 2022-10-25 江苏恒瑞医药股份有限公司 抗cea抗体及其应用
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
CA3148694A1 (en) 2019-09-03 2021-03-11 Romas Kudirka Aminoquinoline compounds, immunoconjugates, and uses thereof
BR112022004995A2 (pt) 2019-09-18 2022-06-21 Lamkap Bio Alpha AG Anticorpos biespecíficos contra ceacam5 e cd3
JP2022549344A (ja) 2019-09-28 2022-11-24 アスクジーン・ファーマ・インコーポレイテッド サイトカインプロドラッグおよびデュアルプロドラッグ
US20220347310A1 (en) 2019-09-30 2022-11-03 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
IL292396A (en) 2019-10-25 2022-06-01 Bolt Biotherapeutics Inc Thianozapine immunoconjugates and uses thereof
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
JP2023533533A (ja) 2020-07-10 2023-08-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、当該細胞に対して放射性ヌクレオチドを標的化する抗体
CA3186059A1 (en) 2020-08-13 2022-02-17 Romas Kudirka Pyrazoloazepine immunoconjugates, and uses thereof
MX2023002041A (es) 2020-08-20 2023-04-27 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para mesotelina.
IL300497A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Compositions and methods for treating CEACAM-positive cancer
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
WO2022125891A2 (en) 2020-12-11 2022-06-16 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
WO2022133042A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Cea5 binding molecules and uses thereof
WO2022130348A1 (en) 2020-12-18 2022-06-23 Lamkap Bio Beta Ag Bispecific antibodies against ceacam5 and cd47
JP2024504931A (ja) 2021-01-12 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体
US20240173442A1 (en) 2021-01-13 2024-05-30 Hoffmann-La Roche Inc. Combination therapy
CN112557662B (zh) * 2021-02-22 2021-07-06 和卓生物科技（上海）有限公司 一种结直肠癌检测试剂盒
KR20230163450A (ko) 2021-03-26 2023-11-30 볼트 바이오테라퓨틱스 인코퍼레이티드 2-아미노-4-카복사마이드-벤즈아제핀 면역접합체 및 이의 용도
TW202304520A (zh) 2021-03-26 2023-02-01 美商博特生物治療公司 ２－胺基－４－羧醯胺－苯并氮呯免疫結合物及其用途
CN115819596A (zh) * 2021-09-17 2023-03-21 优迈生物科技(连云港)有限公司 一种靶向人ceacam5/6的抗体、制备方法和应用
WO2023170474A1 (en) 2022-03-07 2023-09-14 Novimmune Sa Cd28 bispecific antibodies for targeted t cell activation
WO2023180489A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
WO2024110905A1 (en) 2022-11-24 2024-05-30 Beigene, Ltd. Anti-cea antibody drug conjugates and methods of use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO1999043817A1 (en) * 1998-02-25 1999-09-02 The Dow Chemical Company High affinity humanized anti-cea monoclonal antibodies
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
DE60142971D1 (de) 2000-07-31 2010-10-14 Biolex Therapeutics Inc Expression biologisch aktiver polypeptide in wasserlinse
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR101001243B1 (ko) 2001-12-27 2010-12-17 글리코파이, 인크. 포유동물-유형 탄수화물 구조의 설계 방법
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2478294C (en) 2002-03-19 2013-09-03 Plant Research International B.V. Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
WO2003084570A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
EP1539966B1 (en) 2002-09-12 2010-06-30 Greenovation Biotech GmbH Protein production method
WO2004057002A2 (en) 2002-12-20 2004-07-08 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2542885T3 (es) 2003-01-22 2015-08-12 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
EP1627062A1 (en) 2003-05-14 2006-02-22 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
SI2471813T1 (sl) * 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
EP2395026B1 (en) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
MX339608B (es) * 2009-08-31 2016-05-31 Roche Glycart Ag Anticuerpos del antigeno carcinoembrionario (cea).
CA2773515C (en) 2009-09-29 2015-04-28 Roche Glycart Ag Bispecific death receptor agonistic antibodies
DK3489255T3 (da) * 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
UA115030C2 (uk) 2011-03-02 2017-09-11 Рош Глікарт Аг Антитіло, яке зв'язується зі зв'язаним з мембраною карциноембріональним антигеном (сеа)
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AR092044A1 (es) * 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
KR20210094673A (ko) * 2013-02-26 2021-07-29 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
KR20150122203A (ko) * 2013-02-26 2015-10-30 로슈 글리카트 아게 T 세포 활성화 이중특이적 항원 결합 분자
LT3186283T (lt) * 2014-08-29 2020-03-10 F. Hoffmann-La Roche Ag Kombinuotoji terapija į naviką nutaikytais il-2 imunocitokinais ir antikūnais prieš žmogaus pd-l1

Also Published As

Publication number Publication date
US20160229923A1 (en) 2016-08-11
US20120251529A1 (en) 2012-10-04
EP3333193A1 (en) 2018-06-13
TWI553016B (zh) 2016-10-11
HRP20180147T1 (hr) 2018-02-23
KR20140021588A (ko) 2014-02-20
HUE036229T2 (hu) 2018-06-28
MX2013009664A (es) 2013-10-30
CN103403029B (zh) 2015-11-25
AU2012222463B9 (en) 2017-05-25
PE20141017A1 (es) 2014-08-25
JP6046642B2 (ja) 2016-12-21
CR20130359A (es) 2013-11-11
ES2657856T3 (es) 2018-03-07
KR101981342B1 (ko) 2019-05-22
BR112013021460A2 (pt) 2016-10-25
US20180079827A1 (en) 2018-03-22
MX347590B (es) 2017-05-03
UA115030C2 (uk) 2017-09-11
CA2827722A1 (en) 2012-09-07
US9206260B2 (en) 2015-12-08
MY164647A (en) 2018-01-30
IL227482A0 (en) 2013-09-30
AU2012222463A1 (en) 2013-07-25
IL227482B (en) 2019-10-31
US20190185583A1 (en) 2019-06-20
DK2681244T3 (da) 2018-01-29
US8642742B2 (en) 2014-02-04
US20140212408A1 (en) 2014-07-31
SI2681244T1 (en) 2018-03-30
EP2681244B1 (en) 2017-11-29
JP2014509200A (ja) 2014-04-17
NZ614125A (en) 2015-07-31
ZA201305323B (en) 2016-02-24
EA029300B1 (ru) 2018-03-30
CN103403029A (zh) 2013-11-20
PL2681244T3 (pl) 2018-04-30
AU2012222463B2 (en) 2017-05-04
ECSP13012859A (es) 2013-10-31
MA34927B1 (fr) 2014-02-01
CL2013002203A1 (es) 2013-12-06
EA201300978A1 (ru) 2014-02-28
TW201249873A (en) 2012-12-16
SG192972A1 (en) 2013-09-30
BR112013021460B1 (pt) 2022-12-20
US20230365711A1 (en) 2023-11-16
EP2681244A1 (en) 2014-01-08
CA2827722C (en) 2020-05-12
AR085591A1 (es) 2013-10-16
HK1187056A1 (zh) 2014-03-28
US20220002441A1 (en) 2022-01-06
CO6781491A2 (es) 2013-10-31
WO2012117002A1 (en) 2012-09-07
NO2681244T3 (sr) 2018-04-28
AU2012222463A8 (en) 2013-09-05
LT2681244T (lt) 2018-02-12
PT2681244T (pt) 2018-01-24

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
HK1187056A1 (zh) 抗體
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
AP2014008102A0 (en) Anti-FcRn antibodies
EP2841082A4 (en) ANTIBODIES REGULATED BY PROTEASES
EP2875051A4 (en) ANTIBODIES AGAINST SIGLEC-15
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof -15
EP2758430A4 (en) ANTI-C-MET ANTIBODY
TWI563004B (en) Anti-hxcr1 antibody
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
GB201116342D0 (en) Antigen combinations